Search

Your search keyword '"Ahmed H. Mekkawy"' showing total 2 results
Start Over Author "Ahmed H. Mekkawy" Journal discover oncology
2 results on '"Ahmed H. Mekkawy"'

1. The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study

Author

Kevin Ke, Krishna Pillai, Ahmed H. Mekkawy, Javed Akhter, Samina Badar, Sarah J. Valle, and David L. Morris

Subjects
Pseudomyxoma peritonei, PMP, Bromelain, Acetylcysteine, BromAc®, Blood, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Intraperitoneal administration of BromAc (bromelain + acetylcysteine) is currently undergoing a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on analysis of routine blood parameters before and after treatment for a series of 25 patients in this trial. Blood parameters assessed included full blood count, electrolytes, urea, and creatinine, liver function tests, coagulation studies, as well as inflammatory markers (CRP). Certain parameters such as CRP, and white cell count, were significantly elevated after treatment whilst serum albumin level was reduced indicating an inflammatory reaction. However, liver enzymes, coagulation studies, and other parameters were not affected. Therefore, there are no additional safety signals evident upon analysis of routine blood parameter testing.

Published
2021
Full Text
View/download PDF

2. The effect of intraperitoneal administration of BromAc on blood parameters: phase 1 study

Author

Samina Badar, Sarah J. Valle, David L. Morris, Kevin Ke, Javed Akhter, Ahmed H. Mekkawy, and Krishna Pillai

Subjects
Cancer Research, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Phases of clinical research, Gastroenterology, chemistry.chemical_compound, Endocrinology, Internal medicine, Coagulation testing, Medicine, Pseudomyxoma peritonei, RC254-282, Creatinine, medicine.diagnostic_test, Endocrine and Autonomic Systems, business.industry, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Molecular medicine, PMP, Acetylcysteine, BromAc®, Blood, Oncology, chemistry, Urea, Bromelain, business, Liver function tests, Blood parameters
Abstract

Intraperitoneal administration of BromAc (bromelain + acetylcysteine) is currently undergoing a phase 1 clinical trial for pseudomyxoma peritonei at our institution. This study reports on analysis of routine blood parameters before and after treatment for a series of 25 patients in this trial. Blood parameters assessed included full blood count, electrolytes, urea, and creatinine, liver function tests, coagulation studies, as well as inflammatory markers (CRP). Certain parameters such as CRP, and white cell count, were significantly elevated after treatment whilst serum albumin level was reduced indicating an inflammatory reaction. However, liver enzymes, coagulation studies, and other parameters were not affected. Therefore, there are no additional safety signals evident upon analysis of routine blood parameter testing.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results